Novum Pharmaceutical Research Services, a contract research organization serving the pharmaceutical industry in Phase I-Phase IV clinical trials and related services, opened its new, 55,000 square foot, early-stage clinical facility in Houston, Texas, which is scheduled to be operational this summer.
The GCP-compliant facility is being custom-built in Houston's Westchase district, a short distance from Novum's current clinics. The new facility will have seven research units that are designed to make the most efficient use of its 225 beds. Additionally, a 12-bed intensive monitoring unit will allow for early phase research studies requiring continuous cardiac and other specialized safety monitoring. The floor plan and layout will provide a high degree of flexibility in space planning to handle multiple types of study designs.
"This exciting new facility reflects Novum's continued growth and our deep commitment to our clients' needs," said Christopher H. Chamberlain, Novum's Chief Executive Officer. "Like our other research facilities, it will provide a safe, convenient, and pleasant environment for our study participants," he added.
"While our employees and study participants truly make the difference at Novum, bringing this state-of-the-art facility online will raise the bar for Novum and the industry," said Dr. Darin Brimhall, Novum's Vice President of Clinic Operations.